Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells
International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, has received positive early results from animal trials designed to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery that offers an improved alternative to LASIK.
generic viagra online
Advances In Lab-Grown Motor Nerves Can Lead To Cures For Diabetic Neuropathy And Help Further Understand Multiple Sclerosis And Related Conditions
In the July issue of Biomaterials, published by Elsevier, researchers from the University of Central Florida (UCF) report on the first lab-grown motor nerves that are insulated and organized just like they are in the human body. The model system will drastically improve understanding of the causes of myelin-related conditions, such as diabetic neuropathy and later, possibly multiple sclerosis (MS). In addition, the model system will enable the discovery and testing of new drug therapies for these conditions.
News of the day
What Are Kidney Stones? What Causes Kidney Stones?
Kidney stones, usually comprised of a compound called calcium oxalate, are the result of a build-up of dissolved minerals on the inner lining of the kidneys. These deposits can grow to the size of a golf ball while maintaining a sharp, crystalline structure. They may be small and pass unnoticed out of the urinary tract, but they may also cause extreme pain upon exiting. Kidney stones that remain inside the body can lead to many conditions, including severe pain and ureter (the tube connecting the kidney and bladder) blockage that obstructs the path urine uses to leave the body.
Public Health

BioPartners GmbH Withdraws Its Application For Biferonex (interferon Beta-1a)

The European Medicines Agency has been formally notified by BioPartners GmbH of its decision to withdraw its application for Biferonex (interferon beta-1a), 6 million-international-unit solution for injection, prefilled syringes for subcutaneous administration. Biferonex was expected to be used to treat patients with relapsing-remitting multiple sclerosis characterised by two or more exacerbations of neurological symptoms in the previous two years. The application for the marketing authorisation for Biferonex was submitted to the Agency on 24 July 2007. On 19 February 2009, the Agency"s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation. Following this, the company requested a re-examination of the opinion, which was under review by the CHMP at the time of the withdrawal. The company stated in its official letter that its decision to withdraw the application was based on the fact that the additional information provided in support of the re÷¬examination had not changed the Committee"s view on the benefit-risk balance of Biferonex. More information about Biferonex and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website after the next CHMP meeting of 22-25 June 2009. Notes 1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage. 2. This press release, together with other information on the work of the Agency, can be found on the Agency"s website: http://www.emea.europa.eu EMEA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009